DHHS Adult ARV Guidelines
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Potential increased risk of ubrogepant adverse effects
Management
If coadministering, avoid taking a second dose of ubrogepant within 24 hours
Info Source
